lineage cell therapeutics inc 2025年季度报告

FORM10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedSeptember 30,2025 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from _________ to ________Commission file number001-12830 Lineage Cell Therapeutics, Inc.(Exact name of registrant as specified in its charter) California94-3127919(State or other jurisdiction ofincorporation or organization)(IRS EmployerIdentification No.) 2173 Salk Avenue,Suite 200Carlsbad,California92008(Address of principal executive offices) (Zip code) (Registrant’s telephone number, including area code) (442)287-8990 Securities registered pursuant to Section 12(b) of the Act Name of exchange on which registered NYSEAmerican LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file suchreports), and (2) has been subject to such filing requirements for the past 90 days.☒Yes☐No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files).☒Yes☐No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒Emerging growth company☐ Accelerated filer☐Smaller reporting company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).☐Yes☒No The number of common shares outstanding as of October 31, 2025 was230,327,537. Lineage Cell Therapeutics, Inc.Table of Contents PART I.FINANCIAL INFORMATION5Item 1.Financial Statements (Unaudited)5Condensed Consolidated Balance Sheets5Condensed Consolidated Statements of Operations6Condensed Consolidated Statements of Comprehensive Loss7Condensed Consolidated Statements of Changes in Shareholders' Equity8Condensed Consolidated Statements of Cash Flows10Notes to the Condensed Consolidated Interim Financial Statements11Item 2.Management’s Discussion and Analysis of Financial Condition and Result of Operations31Item 3.Quantitative and Qualitative Disclosures about Market Risk40Item 4.Controls and Procedures40PART II.OTHER INFORMATION41Item 1.Legal Proceedings41Item 1A.Risk Factors41Item 2.Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities41Item 3.Defaults Upon Senior Securities41Item 4.Mine Safety Disclosures41Item 5.Other Information41Item 6.Exhibits42Signatures43 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, asamended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that involve substantial risksand uncertainties. The forward-looking statements are contained principally in Part I, Item 2. “Management’s Discussion andAnalysis of Financial Condition and Results of Operations” of this report, but are also contained elsewhere in this report. We makesuch forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 andother federal securities laws. All statements other than statements of historical fact contained in this report are forward-lookingstatements.In some cases, you can identify forward-looking statements by the words “may,” “might,” “will,” “could,” “would,”“should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue”and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future.Forward-looking statements in this report include, but are not limited to, statements about: •the potential to receive developmental, regulatory, and commercialization milestone and royalty payments under ourCollaboration and License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc.;•our continued ability to successfully manufacture our product candidates in a reproducible, scalable, and cost-effectivemanner, for clinical development and, if ap